Bambusa Therapeutics任命梁浩博士为董事会成员，并成立科学顾问委员会-动脉网

Bambusa Therapeutics Appoints Howard Liang, Ph.D. to its Board of Directors and Establishes Scientific Advisory Board

CISION 等信源发布 2026-07-15 20:59



可切换为仅中文







Dr. Liang brings deep biopharma finance, strategy, and capital markets expertise to support the company's next phase of growth

梁博士凭借其在生物医药金融、战略及资本市场领域的深厚专长，助力公司开启下一阶段的成长。

Bambusa also forms a Scientific Advisory Board of globally recognized leaders in biopharma, dermatology, and respiratory medicine to guide its immunology and inflammation pipeline

Bambusa 还组建了一个由全球生物制药、皮肤科和呼吸医学领域公认领袖组成的科学顾问委员会，以指导其免疫学与炎症产品管线的研发。

BOSTON

波士顿

，

July 15, 2026

2026年7月15日

/PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa Therapeutics or Bambusa), a clinical-stage biotechnology company advancing next-generation, long-acting bispecific antibodies for immunology and inflammation (I&I), today announced the appointment of Howard Liang, Ph.D. to its Board of Directors, along with the formation of the company's Scientific Advisory Board.

/美通社/ -- 临床阶段生物技术公司Bambusa Therapeutics, Inc.（简称“Bambusa Therapeutics”或“Bambusa”）致力于推进用于免疫学与炎症（I&I）领域的下一代长效双特异性抗体，今日宣布任命Howard Liang博士为公司董事会成员，并成立公司科学顾问委员会。

Dr. Liang is an accomplished biotechnology executive with more than three decades of leadership experience spanning biotechnology management, financing, strategy, and research at leading biopharmaceutical companies and top-tier investment firms..

梁博士是一位成就卓著的生物技术高管，拥有三十多年的领导经验，涵盖领先生物制药公司和顶级投资机构的生物技术管理、融资、战略和研究等领域。

'We are pleased to welcome Howard to Bambusa's Board of Directors,' said Shanshan Xu, M.D., Ph.D., Founder and Chief Executive Officer of Bambusa Therapeutics. 'Howard brings exceptional expertise across biotechnology financing, corporate strategy, and operational leadership, and his deep experience guiding high-growth companies through pivotal milestones will be invaluable as Bambusa matures.

“我们很高兴欢迎霍华德加入Bambusa的董事会，”Bambusa Therapeutics的创始人兼首席执行官徐姗姗博士表示。“霍华德在生物技术融资、企业战略和运营领导方面拥有卓越的专业知识，他在指导高增长公司度过关键里程碑方面的丰富经验，对于Bambusa的成长将具有不可估量的价值。”

We look forward to benefiting from his counsel as we advance our pipeline and work toward establishing Bambusa as a leading I&I company.'.

我们期待在推进产品管线、致力于将Bambusa打造为领先的免疫与炎症（I&I）领域企业的过程中，受益于他的专业指导。

Dr. Liang most recently served as President and Chief Financial Officer of Tessera Therapeutics (Tessera), a leading genetic medicine company, for more than four years and was instrumental to the company's strategy and growth from the platform stage to clinical development. Prior to joining Tessera, Dr.

梁博士最近曾在领先的基因医学公司Tessera Therapeutics（Tessera）担任总裁兼首席财务官超过四年，在该公司从平台阶段到临床开发的战略制定和增长过程中发挥了重要作用。在加入Tessera之前，梁博士

Liang was Chief Financial Officer and Chief Strategy Officer at BeiGene (now BeOne Medicines) for six years, where he helped drive the company's transition from a research organization with fewer than 200 employees to a fully integrated global biotechnology company with more than 6,000 employees on five continents.

梁先生在百济神州（现更名为BeOne Medicines）担任首席财务官兼首席战略官六年，期间他助力公司从一家员工不足200人的研发机构，转型为一家遍布五大洲、拥有超过6000名员工的全方位整合全球生物技术公司。

Dr. Liang also led BeiGene's three IPOs on NASDAQ and the stock exchanges in Hong Kong and Shanghai, raising a total of more than $11 billion through equity and other financings. Earlier in his career, Dr. Liang spent 15 years as a Wall Street analyst, including at Leerink Partners where he was Managing Director and Head of Biotechnology Equity Research.

梁博士还领导了百济神州在纳斯达克、香港和上海三地证券交易所的三次首次公开募股（IPO），通过股权及其他融资方式筹集资金总额超过110亿美元。在职业生涯早期，梁博士曾担任华尔街分析师长达15年，其中包括在Leerink Partners任职，担任董事总经理兼生物技术股票研究主管。

He began his career in drug discovery research at Abbott Laboratories (AbbVie today). Dr. Liang is on the Board of Tenacia Biotechnology and served as a member of the inaugural Biotech Advisory Panel of Hong Kong Stock Exchange. Dr. Liang received his Ph.D. in Biochemistry and Molecular Biology and M.B.A.

他在雅培实验室（现为艾伯维）开启了药物发现研究的职业生涯。梁博士是Tenacia Biotechnology的董事会成员，并曾担任香港交易所首届生物科技咨询小组成员。梁博士拥有生物化学与分子生物学博士学位以及工商管理硕士学位。

from The University of Chicago and his B.S. in Chemistry from Peking University..

芝加哥大学，以及北京大学化学理学学士学位。

'I am excited to join Bambusa's Board of Directors and support the company as it advances its differentiated pipeline and long-term vision,' said Howard Liang, Ph.D. 'Bambusa has built a compelling foundation with strong scientific capabilities, a clear strategic focus, and the potential to address significant unmet patient needs.

“我很高兴加入Bambusa的董事会，并在公司推进其差异化产品管线和长期愿景的过程中提供支持。”梁浩博士表示，“Bambusa凭借强大的科研能力、清晰的战略重点以及满足重大未满足患者需求的潜力，奠定了令人信服的基础。”

I look forward to working with the Board and management team to help guide the company through this next phase of growth and development.'.

我期待与董事会和管理团队合作，共同引领公司进入下一个成长与发展阶段。

Separately, Bambusa today announced the formation of its Scientific Advisory Board (SAB) to provide strategic and scientific guidance as the company advances its differentiated I&I pipeline of bispecific antibody candidates. The founding SAB members include Stefan Oschmann, DVM, former Chairman and Chief Executive Officer of Merck KGaA, Darmstadt, Germany, who brings decades of global biopharmaceutical leadership and corporate strategy experience; Eric Simpson, M.D., M.C.R., Professor of Dermatology at Oregon Health & Science University and an internationally recognized expert on atopic dermatitis and chronic inflammatory skin diseases; and Ian Pavord, D.M., FRCP, .

此外，Bambusa 今日宣布成立其科学顾问委员会（SAB），旨在为公司推进其差异化的炎症与免疫（I&I）双特异性抗体候选药物管线提供战略和科学指导。科学顾问委员会的创始成员包括：Stefan Oschmann 兽医博士，德国达姆施塔特默克集团（Merck KGaA）前董事会主席兼首席执行官，拥有数十年的全球生物制药领导力和企业战略经验；Eric Simpson 医学博士、临床研究硕士，俄勒冈健康与科学大学皮肤病学教授，是特应性皮炎和慢性炎症性皮肤病领域的国际公认专家；以及 Ian Pavord 医学博士、英国皇家内科医师学会会员。

FMedSci

英国医学科学院院士

，

Professor of Respiratory Medicine at the University of Oxford and a leading expert in type 2 airway inflammation whose work has helped shape the development of biologic therapies for severe asthma and COPD.

牛津大学呼吸医学教授，2型气道炎症领域的领先专家，其研究成果推动了重度哮喘和慢性阻塞性肺疾病（COPD）生物制剂疗法的发展。

'The caliber of these advisors reflects the ambition of our science,' said Thang Ho, Ph.D., Chief Development Officer of Bambusa Therapeutics. 'Across immunology, dermatology, and respiratory disease, their counsel will challenge our thinking, sharpen our strategy, and accelerate our bispecific medicines toward the patients who need them most.'.

“这些顾问的卓越水准彰显了我们科学事业的雄心，”Bambusa Therapeutics首席开发官Thang Ho博士表示。“在免疫学、皮肤病学和呼吸系统疾病领域，他们的专业指导将挑战我们的思维，精进我们的战略，并加速推动我们的双特异性药物惠及最亟需的患者。”

About Bambusa Therapeutics

关于 Bambusa Therapeutics

Bambusa Therapeutics is a clinical-stage biotechnology company developing a portfolio of next-generation, multi-targeting medicines designed to transform patient care across chronic immunology and inflammation (I&I) diseases. The company's bispecific antibody platform combines advanced protein engineering with half-life extension technology and high-concentration subcutaneous delivery to improve durability, convenience, and clinical differentiation.

Bambusa Therapeutics 是一家处于临床阶段的生物技术公司，正在开发一系列下一代多靶点药物，旨在变革慢性免疫学与炎症（I&I）疾病领域的患者护理。公司的双特异性抗体平台将先进的蛋白质工程技术与半衰期延长技术及高浓度皮下递送技术相结合，以提升药物的持久性、便利性和临床差异化优势。

Bambusa's vision is to deliver transformative medicines for patients across every stage of life and help define the next era of I&I therapies..

Bambusa 的愿景是为处于人生各个阶段的患者提供具有变革意义的药物，并助力定义免疫与炎症（I&I）治疗的新时代。

BBT001 is a first-in-class, half-life-extended bispecific antibody targeting interleukin-4 receptor alpha (IL-4Rα) and interleukin-31 (IL-31) with best-in-disease potential. It is currently in Phase 1b/2a proof-of-concept development for atopic dermatitis (AD) and chronic spontaneous urticaria (CSU)..

BBT001 是一款首创的、半衰期延长的双特异性抗体，靶向白细胞介素-4受体α（IL-4Rα）和白细胞介素-31（IL-31），具有同类最佳的治疗潜力。目前，该药物正处于针对特应性皮炎（AD）和慢性自发性荨麻疹（CSU）的1b/2a期概念验证开发阶段。

BBT002 is a first-in-class, half-life-extended bispecific antibody targeting IL-4Rα and interleukin-5 (IL-5) with platform-in-a-molecule potential. It is currently in Phase 1b/2a proof-of-concept development for Type 2 inflammatory disorders including chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis with nasal polyps (CRSwNP)..

BBT002 是一款首创的、半衰期延长的双特异性抗体，靶向 IL-4Rα 和白细胞介素-5（IL-5），具有“分子内平台”潜力。目前，该药正处于针对包括慢性阻塞性肺疾病（COPD）和伴有鼻息肉的慢性鼻窦炎（CRSwNP）在内的 2 型炎症性疾病的 Ib/IIa 期概念验证开发阶段。

BBT003 and BBT004 are preclinical programs focused on gastroenterology and autoantibody-driven autoimmune diseases, respectively.

BBT003和BBT004是分别专注于胃肠病学和自身抗体驱动的自身免疫性疾病的临床前项目。

For more information, please visit

更多信息，请访问

www.bambusatx.com

. Follow Bambusa on

在社交媒体上关注 Bambusa

领英

。

Contact:

联系方式：